Floating IPN Drug Delivery System for Extended Release
Summary
USPTO published patent application US20260096986A1 covering pharmaceutical compositions with a floating interpenetrating polymer network (IPN) system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent. Upon oral ingestion, the compositions form a floating IPN in situ that provides extended release of the entrapped drug for at least approximately 3 hours. The application was filed on December 12, 2025, under application number 19418060.
What changed
USPTO published application US20260096986A1 for pharmaceutical compositions comprising a floating interpenetrating polymer network (IPN) forming system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent that together form a floating IPN in situ upon oral ingestion. The floating IPN provides extended drug release for at least approximately 3 hours. CPC classifications include A61K 9/0065, A61K 9/1617, A61K 9/1652, A61K 9/1664, A61K 9/5146, A61K 31/197, and A61K 47/585.
Pharmaceutical manufacturers and drug developers working on extended-release oral formulations should review these published claims to assess potential overlap with their own development programs. The published application does not itself create compliance obligations but establishes published priority dates for the claimed IPN drug delivery technology.
What to do next
- Monitor for updates
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM
Application US20260096986A1 Kind: A1 Apr 09, 2026
Inventors
Paras Rameshlal JAIN, Sachin Vasant CHAUDHARI
Abstract
Drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the drug entrapped therein for at least about 3 hours.
CPC Classifications
A61K 9/0065 A61K 9/1617 A61K 9/1652 A61K 9/1664 A61K 9/5146 A61K 31/197 A61K 47/585
Filing Date
2025-12-12
Application No.
19418060
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.